Immune Design Quick Ratio (IMDZ) starting from the fourth quarter 2018 to fourth quarter 2017, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Immune Design Corp.  (IMDZ)

Immune Design's Quick Ratio

IMDZ's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2018, Quick Ratio fell to 10.84 below Immune Design Corp. average.

Within Major Pharmaceutical Preparations industry 89 other companies have achieved higher Quick Ratio than Immune Design in fourth quarter 2018. While Quick Ratio total ranking in the fourth quarter 2018 has deteriorated compared to the prior quarter from 305 to 307.

Explain Quick Ratio?
How much Cash & cash equivalents IMDZ´s has?
What are IMDZ´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMDZ Quick Ratio (Dec 31 2018)
Q4		 (Sep 30 2018)
Q3		 (Jun 30 2018)
Q2		 (Mar 31 2018)
Q1		 (Dec 31 2017)
Q4
Y / Y Current Liabilities Change -39.08 % -44.23 % -54.2 % -56.95 % -24.62 %
Y / Y Cash & cash equivalent Change -34.82 % 52.67 % 37.75 % 36.46 % 45.28 %
Quick Ratio MRQ 10.84 12.51 15.22 20.61 10.13
IMDZ's Total Ranking # 307 # 305 # 226 # 209 # 330
Seq. Current Liabilities Change 3.05 % 8.63 % 24.41 % -56.26 % -5.65 %
Seq. Cash & cash equivalent Change -10.71 % -10.68 % -8.14 % -11.03 % 109.14 %



Quick Ratio fourth quarter 2018 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 90
Healthcare Sector # 131
Overall Market # 307


Quick Ratio Statistics
High Average Low
20.8 11.48 4.57
(Jun 30 2015)   (Sep 30 2017)




Financial Statements
Immune Design's Current Liabilities $ 9 Millions Visit IMDZ's Balance sheet
Immune Design's Cash & cash equivalent $ 96 Millions Visit IMDZ's Balance sheet
Source of IMDZ's Sales Visit IMDZ's Sales by Geography


Cumulative Immune Design's Quick Ratio

IMDZ's Quick Ratio for the trailling 12 Months

IMDZ Quick Ratio

 (Dec 31 2018)
12 Months		 (Sep 30 2018)
12 Months		 (Jun 30 2018)
12 Months		 (Mar 31 2018)
12 Months		 (Dec 31 2017)
12 Months
Y / Y Current Liabilities TTM Growth -48.83 % -43.96 % -32.5 % -9.05 % 23.78 %
Y / Y Cash & cash equivalent TTM Growth 13.42 % 42.51 % 18.05 % 8.3 % -1.6 %
Quick Ratio TTM 14.34 13.53 10.61 8.14 6.47
Total Ranking TTM # 3769 # 84 # 191 # 4224 # 4377
Seq. Current Liabilities TTM Growth -15.19 % -15.41 % -17.47 % -13.57 % -7.12 %
Seq. Cash & cash equivalent TTM Growth -10.13 % 7.91 % 7.56 % 8.73 % 12.92 %

Quick ratio ranking by company, industry and sector >> Back to IMDZ Financial Strength Comparisons >> Go to Compare IMDZ Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Immune Design's average Cash & cash equivalent, this led to increase in in Immune Design's Quick Ratio to 14.34, above IMDZ average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 401 other companies have achieved higher Quick Ratio than Immune Design. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2018 from 84 to 3769.

Explain Quick Ratio?
How much Cash & cash equivalents IMDZ´s has?
What are IMDZ´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 402
Healthcare Sector # 749
Within the Market # 3769


trailing twelve months Quick Ratio Statistics
High Average Low
17.87 10.06 3.15
(Mar 31 2016)   (Sep 30 2014)




Companies with similar Quick Ratio in the quarter ending Dec 31 2018, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2018 MRQ Cash & cash equivalentDec 31 2018 MRQ Current Liabilities
Aravive Inc   29.42 $ 56.992  Millions$ 1.937  Millions
Entasis Therapeutics Holdings Inc   29.38 $ 85.092  Millions$ 2.896  Millions
Xenon Pharmaceuticals Inc   28.96 $ 119.306  Millions$ 4.119  Millions
Spero Therapeutics Inc   28.47 $ 115.443  Millions$ 4.055  Millions
Medicinova Inc   28.43 $ 62.313  Millions$ 2.192  Millions
Cannapowder Inc   28.35 $ 0.714  Millions$ 0.025  Millions
Aprea Therapeutics Inc   27.79 $ 65.676  Millions$ 2.364  Millions
Psyence Biomedical ltd   27.07 $ 0.430  Millions$ 0.016  Millions
Synthorx, Inc.  26.75 $ 188.356  Millions$ 7.042  Millions
Fulcrum Therapeutics Inc   26.40 $ 72.797  Millions$ 2.757  Millions
Nextcure Inc   25.46 $ 135.173  Millions$ 5.309  Millions
Minerva Neurosciences Inc   24.38 $ 87.997  Millions$ 3.609  Millions
Vyne Therapeutics Inc   23.88 $ 249.170  Millions$ 10.434  Millions
Bridgebio Pharma Inc   23.29 $ 436.482  Millions$ 18.738  Millions
Achillion Pharmaceuticals Inc  22.91 $ 270.977  Millions$ 11.829  Millions
Gossamer Bio Inc   22.51 $ 228.658  Millions$ 10.158  Millions
Iveric Bio Inc   22.35 $ 131.201  Millions$ 5.869  Millions
Gyre Therapeutics Inc   22.25 $ 120.127  Millions$ 5.398  Millions
Genprex Inc   22.18 $ 8.601  Millions$ 0.388  Millions
Marker Therapeutics inc   22.02 $ 61.747  Millions$ 2.804  Millions
Lixte Biotechnology Holdings Inc   21.89 $ 4.273  Millions$ 0.195  Millions
Arcus Biosciences Inc   21.79 $ 274.129  Millions$ 12.579  Millions
Xencor Inc  21.37 $ 294.361  Millions$ 13.774  Millions
Ra Pharmaceuticals Inc   20.57 $ 209.822  Millions$ 10.201  Millions
Mirum Pharmaceuticals Inc   20.26 $ 51.963  Millions$ 2.565  Millions
Innoviva Inc   20.16 $ 114.908  Millions$ 5.700  Millions
Atreca inc   20.05 $ 114.504  Millions$ 5.711  Millions
Crescent Biopharma Inc   20.02 $ 209.970  Millions$ 10.490  Millions
Prothena Corporation Public Limited Company  19.68 $ 427.659  Millions$ 21.727  Millions
Anaptysbio Inc   19.56 $ 427.082  Millions$ 21.836  Millions

Date modified: 2026-09-05T14:00:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.